GAIN THERAPEUTICS, INC Operating Expenses
GAIN THERAPEUTICS, INC (GANX) reported Operating Expenses of $4.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- GAIN THERAPEUTICS, INC operating expenses for the quarter ending 2026-06-30 was $4.68M, a 8.01% decline year-over-year.
- GAIN THERAPEUTICS, INC operating expenses for the quarter ending 2026-03-31 was $5.35M, a 22.52% increase year-over-year.
- GAIN THERAPEUTICS, INC operating expenses for the quarter ending 2025-12-31 was $4.47M, a 34.07% increase year-over-year.
- GAIN THERAPEUTICS, INC operating expenses for the quarter ending 2025-09-30 was $4.79M, a 7.33% increase year-over-year.
- GAIN THERAPEUTICS, INC operating expenses for fiscal 2025 was $18.71M, a 8.06% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC operating expenses for fiscal 2024 was $20.35M, a 8.78% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC operating expenses for fiscal 2023 was $22.31M, a 24.51% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC operating expenses for fiscal 2022 was $17.92M, a 28.06% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.68M 10-Q · filed 2026-08-11 | $10.04M 10-Q · filed 2026-08-11 | $14.50M derived: sum of 3 quarters · filed 2026-08-11 | $19.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $5.35M 10-Q · filed 2026-05-11 | $9.82M derived: sum of 2 quarters · filed 2026-05-11 | $14.61M derived: sum of 3 quarters · filed 2026-05-11 | $19.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $9.25M derived: sum of 2 quarters · filed 2026-03-26 | $14.34M derived: sum of 3 quarters · filed 2026-08-11 | $18.71M 10-K · filed 2026-03-26 |
| 2025-09-30 | $4.79M 10-Q · filed 2025-11-12 | $9.88M derived: sum of 2 quarters · filed 2026-08-11 | $14.24M 10-Q · filed 2025-11-12 | $17.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $5.09M 10-Q · filed 2026-08-11 | $9.46M 10-Q · filed 2026-08-11 | $12.79M derived: sum of 3 quarters · filed 2026-08-11 | $17.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.37M 10-Q · filed 2026-05-11 | $7.70M derived: sum of 2 quarters · filed 2026-05-11 | $12.16M derived: sum of 3 quarters · filed 2026-05-11 | $20.34M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.79M derived: sum of 2 quarters · filed 2026-03-26 | $15.97M derived: sum of 3 quarters · filed 2026-03-26 | $20.35M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.46M 10-Q · filed 2025-11-12 | $12.64M derived: sum of 2 quarters · filed 2025-11-12 | $17.02M 10-Q · filed 2025-11-12 | $21.43M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.18M 10-Q · filed 2025-08-12 | $12.56M 10-Q · filed 2025-08-12 | $16.97M derived: sum of 3 quarters · filed 2025-08-12 | $21.85M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.38M 10-Q · filed 2025-05-14 | $8.78M derived: sum of 2 quarters · filed 2025-05-14 | $13.67M derived: sum of 3 quarters · filed 2025-05-14 | $21.40M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $9.29M derived: sum of 2 quarters · filed 2025-03-27 | $17.02M derived: sum of 3 quarters · filed 2025-03-27 | $22.31M 10-K · filed 2025-03-27 |
| 2023-09-30 | $4.89M 10-Q · filed 2024-11-14 | $12.62M derived: sum of 2 quarters · filed 2024-11-14 | $17.90M 10-Q · filed 2024-11-14 | $22.46M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $7.73M 10-Q · filed 2024-08-08 | $13.02M 10-Q · filed 2024-08-08 | $17.58M derived: sum of 3 quarters · filed 2024-08-08 | $22.33M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.28M 10-Q · filed 2024-05-14 | $9.85M derived: sum of 2 quarters · filed 2024-05-14 | $14.60M derived: sum of 3 quarters · filed 2024-05-14 | $19.87M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $9.31M derived: sum of 2 quarters · filed 2024-03-26 | $14.58M derived: sum of 3 quarters · filed 2024-03-26 | $17.92M 10-K · filed 2024-03-26 |
| 2022-09-30 | $4.75M 10-Q · filed 2023-11-14 | $10.02M derived: sum of 2 quarters · filed 2023-11-14 | $13.36M 10-Q · filed 2023-11-14 | $16.61M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.27M 10-Q · filed 2023-08-10 | $8.60M 10-Q · filed 2023-08-10 | $11.86M derived: sum of 3 quarters · filed 2023-08-10 | $16.52M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.33M 10-Q · filed 2023-05-12 | $6.59M derived: sum of 2 quarters · filed 2023-05-12 | $11.25M derived: sum of 3 quarters · filed 2023-05-12 | $14.85M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $7.92M derived: sum of 2 quarters · filed 2023-03-23 | $11.52M derived: sum of 3 quarters · filed 2023-03-23 | $13.99M 10-K · filed 2023-03-23 |
| 2021-09-30 | $4.66M 10-Q · filed 2022-11-10 | $8.27M derived: sum of 2 quarters · filed 2022-11-10 | $10.74M 10-Q · filed 2022-11-10 | $12.36M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.60M 10-Q · filed 2022-08-08 | $6.08M 10-Q · filed 2022-08-08 | $7.70M derived: sum of 3 quarters · filed 2022-08-08 | $8.53M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.47M 10-Q · filed 2022-05-16 | $4.10M derived: sum of 2 quarters · filed 2022-05-16 | $4.92M derived: sum of 3 quarters · filed 2022-05-16 | $5.46M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $2.45M derived: sum of 2 quarters · filed 2022-03-25 | $2.99M derived: sum of 3 quarters · filed 2022-03-25 | $3.51M 10-K · filed 2022-03-25 |
| 2020-09-30 | $825.78K 10-Q · filed 2021-11-12 | $1.36M derived: sum of 2 quarters · filed 2021-11-12 | $1.88M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $538.84K 10-Q · filed 2021-08-12 | $1.06M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $518.93K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |